EverSource Wealth Advisors LLC Has $35,000 Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

EverSource Wealth Advisors LLC boosted its position in IQVIA Holdings Inc. (NYSE:IQVGet Rating) by 243.2% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 151 shares of the medical research company’s stock after purchasing an additional 107 shares during the period. EverSource Wealth Advisors LLC’s holdings in IQVIA were worth $35,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Pitcairn Co. lifted its stake in IQVIA by 101.8% in the 1st quarter. Pitcairn Co. now owns 2,226 shares of the medical research company’s stock valued at $515,000 after purchasing an additional 1,123 shares during the last quarter. Raymond James & Associates lifted its stake in IQVIA by 4.1% in the 1st quarter. Raymond James & Associates now owns 729,957 shares of the medical research company’s stock valued at $168,773,000 after purchasing an additional 28,899 shares during the last quarter. Meeder Asset Management Inc. acquired a new stake in IQVIA during the first quarter worth approximately $599,000. Primecap Management Co. CA lifted its position in IQVIA by 1.3% during the first quarter. Primecap Management Co. CA now owns 611,177 shares of the medical research company’s stock worth $141,310,000 after acquiring an additional 7,800 shares during the last quarter. Finally, Empirical Finance LLC lifted its position in IQVIA by 12.7% during the first quarter. Empirical Finance LLC now owns 3,538 shares of the medical research company’s stock worth $818,000 after acquiring an additional 398 shares during the last quarter. 86.77% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have issued reports on IQV. Morgan Stanley raised their price objective on shares of IQVIA from $255.00 to $260.00 and gave the stock an “overweight” rating in a research report on Friday, July 22nd. Argus raised their price objective on shares of IQVIA from $260.00 to $275.00 in a research report on Thursday, August 18th. Barclays cut their price objective on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research report on Monday, September 12th. Guggenheim lifted their price target on shares of IQVIA to $246.00 in a research report on Friday, July 22nd. Finally, StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, September 8th. Two equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $275.00.

IQVIA Stock Performance

Shares of NYSE:IQV opened at $205.04 on Monday. The company’s 50 day simple moving average is $224.94 and its 200 day simple moving average is $220.82. The stock has a market capitalization of $38.24 billion, a price-to-earnings ratio of 34.23, a price-to-earnings-growth ratio of 1.87 and a beta of 1.34. The company has a debt-to-equity ratio of 2.36, a current ratio of 0.96 and a quick ratio of 0.96. IQVIA Holdings Inc. has a 1 year low of $194.67 and a 1 year high of $285.61.

IQVIA (NYSE:IQVGet Rating) last posted its earnings results on Thursday, July 21st. The medical research company reported $2.44 earnings per share for the quarter, topping analysts’ consensus estimates of $2.22 by $0.22. The firm had revenue of $3.54 billion for the quarter, compared to analysts’ expectations of $3.49 billion. IQVIA had a net margin of 8.21% and a return on equity of 30.21%. The company’s revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.94 earnings per share. As a group, research analysts predict that IQVIA Holdings Inc. will post 9.4 EPS for the current fiscal year.

IQVIA Company Profile

(Get Rating)

IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

See Also

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQVGet Rating).

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.